Indoco Remedies Limited (BOM:532612)
210.05
+5.40 (2.64%)
At close: Feb 10, 2026
Indoco Remedies Employees
Indoco Remedies had 6,000 employees as of September 30, 2025. The number of employees did not change compared to the same quarter last year.
Employees
6,000
Change
n/a
Growth
n/a
Revenue / Employee
2.93M INR
Profits / Employee
-189.81K INR
Market Cap
19.42B
Employees Chart
Employees History
| Date | Employees | Change (1Y) | Growth (1Y) |
|---|---|---|---|
| Sep 30, 2025 | 6,000 | 0 | - |
| Jun 30, 2025 | 6,000 | 0 | - |
| Mar 31, 2025 | 6,051 | 122 | 2.06% |
| Dec 31, 2024 | 6,000 | 0 | - |
| Sep 30, 2024 | 6,000 | 0 | - |
| Jun 30, 2024 | 6,000 | 0 | - |
| Mar 31, 2024 | 5,929 | -169 | -2.77% |
| Dec 31, 2023 | 6,000 | 0 | - |
| Sep 30, 2023 | 6,000 | -1,000 | -14.29% |
| Jun 30, 2023 | 6,000 | -1,000 | -14.29% |
| Mar 31, 2023 | 6,098 | 171 | 2.89% |
| Dec 31, 2022 | 6,000 | 0 | - |
| Sep 30, 2022 | 7,000 | 1,000 | 16.67% |
| Jun 30, 2022 | 7,000 | 1,000 | 16.67% |
| Mar 31, 2022 | 5,927 | -154 | -2.53% |
| Dec 31, 2021 | 6,000 | 500 | 9.09% |
| Sep 30, 2021 | 6,000 | 500 | 9.09% |
| Jun 30, 2021 | 6,000 | 500 | 9.09% |
| Mar 31, 2021 | 6,081 | 221 | 3.77% |
| Dec 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Sep 30, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Jun 30, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Mar 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Sep 30, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Jun 30, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Mar 31, 2013 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Mar 31, 2011 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Related Stocks
| Company Name | Employees |
|---|---|
| Unichem Laboratories | 3,142 |
| Hikal | 2,062 |
| Morepen Laboratories | 1,814 |
| Gufic Biosciences | 1,484 |
| TTK Healthcare | 1,339 |
| Kwality Pharmaceuticals | 997 |
| Bliss GVS Pharma | 966 |
| Syncom Formulations (India) | 744 |
Indoco Remedies News
- 7 days ago - Indoco Remedies Q3 Results: Revenue rises 8.5% YoY to Rs 445.4 crore, net loss at Rs 29.8 crore - Business Upturn
- 3 months ago - Indoco Remedies Ltd (BOM:532612) Q2 2026 Earnings Call Highlights: Revenue Growth and Strategic ... - GuruFocus
- 3 months ago - Q2 2026 Indoco Remedies Ltd Earnings Call Transcript - GuruFocus
- 5 months ago - Indoco Remedies’ Patalganga API facility clears USFDA inspection with zero observations - Business Upturn
- 6 months ago - Why are Indoco Remedies shares up 2% today? Explained - Business Upturn
- 6 months ago - Indoco Remedies gets USFDA nod for generic Rivaroxaban tablets; eyes growth in US Market - Business Upturn
- 6 months ago - Indoco Remedies signs Sale and Leaseback Agreemen for Waluj facility assets - Business Upturn
- 9 months ago - Indoco Remedies launches Ticagrelor tablets in UK through subsidiary - Business Upturn